Anticancer Class
Showing 7 drugs
starting with: P
Paclitaxel
Brand: Taxol (global) / Paclitax (IN/BD)
Class: Anticancer
Subclass: Taxane (microtubule stabilizer)
PK:
t½ 20 hours | Clearance: hepatic
Max Dose: not added
Max Dose: not added
severe
AE: Neutropenia, peripheral neuropathy, hypersensitivity reactions, alopecia
AE: Neutropenia, peripheral neuropathy, hypersensitivity reactions, alopecia
Palbociclib
Brand: Ibrance (US/EU) / Palbociclib (IN/BD)
Class: Anticancer
Subclass: CDK4/6 inhibitor
PK:
t½ 29 hours | Clearance: hepatic
Max Dose: 125 day
Max Dose: 125 day
severe
AE: Neutropenia, infections, stomatitis, fatigue
AE: Neutropenia, infections, stomatitis, fatigue
Pembrolizumab
Brand: Keytruda (global)
Class: Anticancer
Subclass: PD-1 Immune Checkpoint Inhibitor
PK:
t½ 528 hours | Clearance: hepatic
Max Dose: 200 day
Max Dose: 200 day
life-threatening
AE: Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, thyroid dysfunction
AE: Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, thyroid dysfunction
Pemetrexed
Brand: Alimta (global)
Class: Anticancer
Subclass: Antimetabolite (multitargeted antifolate)
PK:
t½ 3.5 hours | Clearance: renal
Max Dose: not added
Max Dose: not added
moderate
AE: Myelosuppression, fatigue, rash, mucositis
AE: Myelosuppression, fatigue, rash, mucositis
Pertuzumab
Brand: Perjeta (global) / Pertuzumab (IN/BD)
Class: Anticancer
Subclass: HER2 monoclonal antibody
PK:
t½ 432 hours | Clearance: hepatic
Max Dose: 420 day
Max Dose: 420 day
severe
AE: Diarrhoea, rash, neutropenia, infusion reactions; potential cardiotoxicity (esp. with trastuzumab); embryo-fetal toxicity
AE: Diarrhoea, rash, neutropenia, infusion reactions; potential cardiotoxicity (esp. with trastuzumab); embryo-fetal toxicity
Pomalidomide
Brand: Pomalyst (global)
Class: Anticancer
Subclass: Immunomodulatory agent (IMiD)
PK:
t½ 7.5 hours | Clearance: hepatic
Max Dose: not added
Max Dose: not added
severe
AE: Myelosuppression, fatigue, thrombosis risk, rash
AE: Myelosuppression, fatigue, thrombosis risk, rash
Pralsetinib
Brand: Gavreto (global)
Class: Anticancer
Subclass: RET inhibitor
PK:
t½ 22 hours | Clearance: hepatic
Max Dose: 400 day
Max Dose: 400 day
severe
AE: Interstitial lung disease/pneumonitis, hypertension, hepatotoxicity, neutropenia
AE: Interstitial lung disease/pneumonitis, hypertension, hepatotoxicity, neutropenia